Stock Market Reacts to Kennedy's HHS Appointment

President-elect Donald Trump has announced the appointment of Robert F. Kennedy Jr., a known vaccine skeptic, as the head of the Department of Health and Human Services, causing significant controversy. Kennedy has a history of spreading misinformation about vaccines, which many public health officials fear could undermine vaccination efforts and public trust in science-based health policies. His appointment has been criticized by politicians and health experts, with concerns over his lack of relevant medical expertise and promotion of debunked theories. The announcement has also impacted the stock market, with major vaccine manufacturers like Moderna and Pfizer experiencing significant declines. Critics point out the potential risks to public health and the pharmaceutical industry, given Kennedy's stance on vaccines and other health issues. Despite the backlash, Trump's administration has defended the appointment, emphasizing Kennedy's goals to combat chronic diseases and reduce pharmaceutical influence.